
Release date: 2026-03-16 16:22:26 Article From: Lucius Laos Recommended: 5
Elacestrant, while exerting its therapeutic effects, can also cause some side effects. Patients taking Elacestrant need to closely monitor their own condition.
After taking Elacestrant, mild discomfort may occur. These symptoms usually do not require medical attention and will often gradually lessen for most patients as their bodies adjust to the medication during treatment. If symptoms persist, consult your doctor immediately:
Stomach acid or sour stomach.
Hiccups.
Constipation.
Decreased appetite.
Diarrhea.
Headache.
Heartburn.
Hot flashes.
Indigestion.
Muscle or bone pain.
Nausea.
Stomach discomfort, upset, or pain.
Unusual tiredness or weakness.
Vomiting.
Very common (10% or more): Hot flashes (11%).
Uncommon (0.1% - 1%): Cardiac arrest, venous thromboembolism.
Common (1% to 10%): Rash.
Very common (10% or more): Nausea (35%), vomiting (19%), diarrhea (13%), constipation (12%), abdominal pain (11%), dyspepsia (10%).
Uncommon (0.1% to 1%): Diverticulitis.
Frequency not reported: Stomatitis, gastroesophageal reflux disease. Gastrointestinal disorders were reported more frequently in patients aged 75 years or older.
Very common (10% or more): Decreased hemoglobin (26%), anemia.
Common (1% - 10%): Decreased lymphocyte count.
Uncommon (0.1% - 1%): Acute liver failure.
Very common (10% or more): Increased AST (29%), increased ALT (17%).
Very common (10% or more): Increased cholesterol (30%), increased triglycerides (27%), decreased sodium (16%), decreased appetite (15%), decreased calcium, decreased potassium, increased blood alkaline phosphatase.
Very common (10% or more): Musculoskeletal pain (41%), arthralgia, back pain.
Frequency not reported: Bone pain, pain in extremity, musculoskeletal chest pain.
Very common (10% or more): Headache (12%).
Common (1% to 10%): Syncope.
Frequency not reported: Dizziness.
Frequency not reported: Insomnia.
Very common (10% or more): Increased creatinine (16%).
Common (1% - 10%): Urinary tract infection.
Frequency not reported: Dyspnea, cough.
Very common (10% or more): Fatigue (26%).
Common (1% to 10%): Asthenia.
Uncommon (0.1% - 1%): Septic shock, fatal adverse reaction (cause unknown).
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1702025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:4092024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:1672025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1882025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1662025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:2002025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1822025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1742025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: